AUROBINDO

August 12, 2021

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir,

Sub: Outcome of Board Meeting held on August 12, 2021.

The Board of Directors of the Company at its meeting held today, August 12, 2021, has inter alia, considered and approved:-

1. the Un-audited Financial Results of the Company for the First Quarter ended June 30, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company.

2. an Interim Dividend @ 150% i.e. Rs.1.50 (Rupee one and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2021-22.

   Please refer to our letter dated August 3, 2021 wherein we have informed that the Register of Members and Share Transfer Books of the Company are being closed from **August 24, 2021 to August 26, 2021** (both days inclusive) for the purpose of 34th Annual General Meeting of the Company. We hereby further inform that the aforesaid book closure dates will also be considered to determine the entitlement of the shareholders to the aforesaid interim dividend of 150% i.e. Rs.1.50 (Rupee one and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company for the financial year 2021-22 as approved by the Board on August 12, 2021 and the same will be paid on or before **September 7, 2021.**

3. the Scheme of Amalgamation ("Scheme") pursuant to sections 230-232 and other applicable provisions of the Companies Act, 2013, providing for the amalgamation of Company's wholly owned subsidiaries viz. Auronext Pharma Private Limited and Mviyes Pharma Ventures Private Limited ("Transferor Companies") with Aurobindo Pharma Limited ("Transferee Company").

   The Scheme would be subject to the requisite statutory / regulatory approvals including the approval of the National Company Law Tribunal (Hyderabad Bench).

   We enclose herewith the details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No.CIR/CFD/CMD/4/2015 dated September 9, 2015 in **Annexure-A** to this letter.

AUROBINDO

Further, the Company has entered into definitive agreements today under which the Company will subscribe to fresh equity shares in Cronus Pharma Specialities India Private Limited (Cronus), subject to closing conditions, amounting to Rs. 420 Crores. Cronus is a Hyderabad based generic veterinary pharmaceutical products company engaged in development, manufacturing and sale of veterinary pharmaceutical products. Subsequent to this investment, the Company will own 51% of the Equity share capital of Cronus.

We enclose herewith the details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No.CIR/CFD/CMD/4/2015 dated September 9, 2015 in **Annexure-B** to this letter.

We also enclose a copy of the Press Release on Un-audited Financial Results of the Company for the First Quarter ended June 30, 2021.

The Board meeting commenced at 3.00 p.m. and concluded at 6.45 p.m.

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary

Enclosures: as above.

AUROBINDO PHARMA LTD. HYDERABAD, INDIA

AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370; Fax: +91 40 23747340; Email: info@aurobindo.com

(Rs. In lakhs)

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2021

	Particulars	Quarter ended			Year ended
		30.06.2021	31.03.2021	30.06.2020	31.03.2021
		Unaudited	Audited	Unaudited	Audited
1	**Revenue from operations**				
	(a) Net sales/ Income from operations	**288,564**	410,361	334,354	1,562,218
	(b) Other operating income	**811**	1,042	8,245	20,150
	Total revenue from operations	**289,375**	411,403	342,599	1,582,368
2	**Other income**				
	(a) Foreign exchange gain (net) (refer note 7)	**1,692**	3,963	5,198	18,544
	(b) Others	**2,703**	22,779	6,898	40,442
	Total other income	**4,395**	26,742	12,096	58,986
	Total income (1+2)	**293,770**	438,145	354,695	1,641,354
3	**Expenses**				
	(a) Cost of materials consumed	**154,349**	180,316	180,103	721,573
	(b) Purchase of stock-in-trade	**593**	1,502	514	2,609
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	**(11,171)**	12,733	(38,770)	299
	(d) Employee benefits expense	**43,077**	44,473	42,732	173,543
	(e) Finance costs	**506**	593	1,044	2,868
	(f) Depreciation and amortisation expense	**11,465**	12,407	12,046	48,799
	(g) Other expenses	**61,446**	74,776	61,970	272,362
	Total expenses	**260,265**	326,800	259,639	1,222,053
4	**Profit before tax (1+2-3)**	**33,505**	111,345	95,056	419,301
5	**Tax expense**				
	Current tax	**14,344**	20,898	24,510	104,334
	Deferred tax	**(2,346)**	3,189	(207)	3,676
	Total tax expense	**11,998**	24,087	24,303	108,010
6	**Profit for the period/year (4-5)**	**21,507**	87,258	70,753	311,291
7	**Other Comprehensive Income**				
	Items that will not to be reclassified subsequently to profit or loss:				
	(a) Re-measurement of defined benefit liability	**(246)**	(254)	(482)	(986)
	(b) Income-tax relating to items that will not be reclassified to profit or loss	**86**	88	169	344
8	**Total Comprehensive Income for the period/year (6+7)**	**21,347**	87,092	70,440	310,649
9	Paid-up equity share capital (face value Re. 1 per share)	**5,859**	5,859	5,859	5,859
10	Other equity				1,586,602
11	Earnings per equity share (face value Re. 1 per share)	(not annualised)	(not annualised)	(not annualised)	(Annualised)
	(a) Basic (in Rs.)	**3.67**	14.89	12.07	53.13
	(b) Diluted (in Rs.)	**3.67**	14.89	12.07	53.13



NOTES:

1 The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.

2 The above standalone financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 12 August 2021. The statutory auditors have carried out limited review of the above results for the quarter and year ended 30 June 2021. An unmodified report has been issued by them thereon.

3 The Company operates in only one segment viz., 'Pharmaceutical Products'.

4 Sales of standalone include exports of Rs.289,286 lakhs for the current quarter (30 June 2020: Rs.281,483 lakhs).

5 The Government of India, on 20 September 2019, vide the Taxation Laws (Amendment) Ordinance 2019, the Ordinance inserted a new Section 115BAA in the Income tax Act, 1961, which provides an option to the Company for paying income tax at reduced rates as per the provisions/conditions defined in the said section. The Company is in the process of evaluating the above ordinance and currently the management has proposed to continue with the old tax rates.

6 During the financial year 2019-20, the Board of directors of the Company has approved for amalgamation of the five subsidiary Companies with Aurobindo Pharma Limited, the holding company with the appointed date of 1 April 2019. Accordingly, a Scheme of Amalgamation for merger of APL Healthcare Limited, APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited and Silicon Life Sciences Private Limited (a stepdown wholly owned subsidiary) with the Company was filed before the Hon'ble National Company Law Tribunal, Hyderabad (NCLT). Further, during the previous year, a modified Scheme Amalgamation was filed with the Hon'ble NCLT by way of filing an interlocutory application for removal and complete exclusion of the APL Healthcare Limited as a party to the Scheme of Amalgamation. The Hon'ble NCLT vide order dated 30 March 2021 has approved the modified scheme of amalgamation and a certified copy has been filed by the Company with the Registrar of Companies, Telangana 29 April 2021. Accordingly, the subsidiaries viz. APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited and Silicon Life Sciences Private Limited (a stepdown wholly owned subsidiary) have been merged with Aurobindo Pharma Limited. The appointed date as per the NCLT approved Scheme is 1 April 2019, which is the same as the beginning of the preceding period in the financial statements and hence, in line with the Scheme, the combination has been accounted for from that date as per the requirements of Appendix C to Ind AS 103 "Business Combination". Accordingly, the amounts relating to the three months and year ended 31 March 2021 include the impact of the business combination and the corresponding amounts for three months ended 30 June 2020 shown in the statement, have been restated after recognising the effect of the Scheme as above.

Impact of the Scheme on the statement of standalone results

Particulars	Quarter ended 30.06.2020	Year ended 31.03.2021
Total income	167	7,261
Total expenses	1,130	9,812
Loss before tax	(963)	(2,551)
Tax expense/(benefit)	(248)	(657)
(Loss) after tax	(715)	(1,894)

7 Foreign exchange gain includes exchange difference arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of Ind AS 23 on borrowing costs.

8 The Company continues to monitor the possible effects that may result from the pandemic relating to COVID-19. The Company continues to take several business continuity measures with a view to ensure minimal disruption with respect to operations including production and distribution activities. The Company has not experienced any significant difficulties with respect to market demand, financing capital expansion projects, collections or liquidity in other markets. Based on internal and external sources of information, current economic environment and future economic indicators, the Company has assessed the financial impact of the COVID-19 situation on its operations particularly on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. Wherever considered necessary an assessment of the impact has been carried out and the necessary adjustments if material have been recorded. However, the impact of the pandemic could be different from those estimated today considering the uncertainties involved. The Company will continue to monitor any material changes to future economic conditions.

9 The Board of Aurobindo Pharma Limited on 27 February 2021 had approved the transfer of its oral formulations business comprised in Unit 10 located at Multiproduct Special Economic Zone, Naidupet, Mandal, SPSR Nellore District, Andhra Pradesh to its wholly-owned subsidiary APL Healthcare Limited through a slump sale. During the current quarter the above undertaking was transferred for consideration of Rs.131,500 lakhs.

10 The Board of Aurobindo Pharma Limited in their meeting held on 1st July 2021 approved the transfer of business undertaking comprised in Unit-4 of the Company, to Eugia Specialities Limited, a wholly owned subsidiary of the Company. The Company is in the process of getting necessary approvals from respective authorities.

11 The Board of Aurobindo Pharma Limited in their meeting held on 31st May 2021 approved Transfer of business undertaking comprised in Unit-16 of the Company, to Wytells Pharma Private Limited, a wholly owned step-down subsidiary of the Company and 100% subsidiary of Eugia Pharma Specialities. The Company is in the process of getting necessary approvals from respective authorities. Hence, no adjustment was made in the books of account for the quarter ended 30 June 2021.

12 The date of implementation of the Code of Wages 2019 and Code on Social Security, 2020 is yet to be notified by the Government. The Company is in the process of assessing the impact of these Codes and will give effect in the financial results when the Rules/Schemes thereunder are notified.

13 The figures of the quarter ended 31 March 2021 are the balancing figures between audited figures in respect of the full financial year upto 31 March 2021 and the unaudited published year to date figures upto 31 December 2020 being the date of the end of the third quarter of the financial year. The standalone results for the nine months ended 31 December 2020 have been subjected to the limited review by the statutory auditors.

14 The Board has approved interim dividend @150% i.e.Re.1.50 (Rupee one and fifty paise only) per equity share of Re.1 (Rupee One only) for the year 2021-22.

By Order of the Board

N. Govindarajan
Managing Director
DIN-00050482

Place: Hyderabad
Date :12 August 2021

www.aurobindo.com

B S R & Associates LLP

Chartered Accountants

Salarpuriya Knowledge City,
Orwell, B Wing, 6th Floor, Unit-3,
Sy No. 83/1, Plot No. 02, Raidurg,
Hyderabad – 500 081 - India

Telephone: +91 40 7182 2000
Fax: +91 40 7182 2399

Limited Review Report on Unaudited Quarterly Standalone Financial results of Aurobindo Pharma Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended ("Listing Regulations")

To
Board of Directors of Aurobindo Pharma Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Aurobindo Pharma Limited ('the Company") for the quarter ended 30 June 2021.

2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

5. The standalone financial results of the Company include the financial results of 5 wholly owned subsidiaries whose standalone financial results reflect total revenue (before inter-company adjustments) of Rs. 14,627 lakhs for the year ended 31 March 2021. These subsidiaries have been merged with the Company vide The Hon'ble National Company Law Tribunal, Hyderabad order dated 30 March 2021. These subsidiaries have been audited by other auditors whose reports have been furnished to us, and our opinion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of such other auditors.

Further, standalone financial results include total revenue (before inter-company adjustments) for the quarter ended 31 March 2021 and 30 June 2020 of Rs. 3,537 lakhs and Rs.1,100 lakhs respectively related to aforesaid subsidiaries. The financial results of the aforesaid subsidiaries for these quarters have not been subjected to review or audit. In our opinion and according to the information and explanations given to us by the Management, the financial results of subsidiaries are not material to the Company.

6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Associates LLP**
Chartered Accountants
Firm Registration Number: 116231W/W-100024

SRIRAM MAHALINGAM

Digitally signed by SRIRAM MAHALINGAM
Date: 2021.08.12 18:25:00 +05'30'

Sriram Mahalingam
Partner
Membership Number: 049642
UDIN:21049642AAAADS5984

Place: Hyderabad
Date: 12 August 2021

AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370; Fax: +91 40 23747340; Email: info@aurobindo.com

(Rs. In lakhs)

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2021

	Particulars	Quarter ended			Year ended
		30.06.2021	31.03.2021	30.06.2020	31.03.2021
		Unaudited	Audited	Unaudited	Audited
1	**Revenue from operations**				
	(a) Net sales/ income from operations	569,185	599,168	583,523	2,455,795
	(b) Other operating income	1,013	982	8,955	21,668
	Total revenue from operations	570,198	600,150	592,478	2,477,463
2	**Other income**				
	(a) Foreign exchange gain (net) (refer note 7)	2,859	1,423	2,222	10,358
	(b) Others	8,131	6,387	9,337	27,726
	Total other income	10,990	7,810	11,559	38,084
	Total income (1+2)	581,188	607,960	604,037	2,515,547
3	**Expenses**				
	(a) Cost of materials consumed	186,005	199,014	209,817	831,727
	(b) Purchase of stock-in-trade	37,324	49,225	60,157	231,542
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	13,294	(7,530)	(29,234)	(73,021)
	(d) Employee benefits expense	86,993	85,440	88,799	353,502
	(e) Finance costs	1,288	1,822	2,107	7,449
	(f) Foreign exchange loss (net) (refer note 7)	-	-	-	-
	(g) Depreciation and amortisation expense	27,969	26,600	25,552	105,538
	(h) Other expenses	125,644	146,534	137,204	600,372
	Total expenses	478,517	501,105	494,402	2,057,109
4	**Profit before share of profit of joint ventures, exceptional items and tax (1+2-3)**	102,671	106,855	109,635	458,438
5	Share of loss of joint ventures, net of tax	(900)	(837)	(1,200)	(5,536)
6	**Profit before exceptional items and tax (4+5)**	101,771	106,018	108,435	452,902
7	**Exceptional items (refer note 4)**	-	(69)	-	(281,458)
8	**Profit before tax (6-7)**	101,771	106,087	108,435	734,360
9	**Tax expense**				
	Current tax	24,316	44,923	36,525	232,536
	Tax credit - Minimum Alternate Tax (MAT)	(2,063)	(354)	-	(354)
	Deferred tax	2,521	(18,600)	(6,406)	(31,205)
	Total tax expense	24,774	25,969	30,119	200,977
10	**Profit for the period/year (8-9)**	76,997	80,118	78,316	533,383
11	Other Comprehensive Income				
	A) Items that will not be reclassified subsequently to profit or loss:				
	i) Re-measurement of defined employee benefit liability	(246)	(232)	(482)	(980)
	ii) Income-tax relating to items that will not be reclassified to profit or loss	86	102	169	370
	(iii) Equity investments through other comprehensive income – net change in fair value	1,291	(339)	-	(359)
	B) Items that will be reclassified subsequently to profit or loss:				
	i) Exchange differences on translating the financial statements of foreign operations	22,002	(8,137)	6,426	1,443
	ii) Income-tax on items that will be reclassified subsequently to profit or loss	-	-	-	-
	Total other comprehensive income for the period/year (net of tax)	23,133	(8,606)	6,113	474
12	**Total Comprehensive income for the period/year (net of tax) (10+11)**	100,130	71,512	84,429	533,857
	Attributable to:				
	Owners of the Parent Company	100,130	71,552	84,419	533,959
	Non-controlling interest	-	(40)	10	(102)
	Out of total comprehensive income above,				
	Profit for the year attributable to:				
	Owners of the Parent Company	76,997	80,158	78,306	533,485
	Non-controlling interest	-	(40)	10	(102)
	Other comprehensive income attributable to:				
	Owners of the Parent Company	23,133	(8,606)	6,113	474
	Non-controlling interest	-	-	-	-
13	Paid-up equity share capital (face value Re. 1 per share)	5,859	5,859	5,859	5,859
14	Other equity				2,187,127
15	Earnings per equity share (face value Re. 1 per share)	(not annualised)	(not annualised)	(not annualised)	(Annualised)
	(a) Basic (in Rs.)	13.14	13.67	13.32	91.04
	(b) Diluted (in Rs.)	13.14	13.67	13.32	91.04

AUROBINDO PHARMA LTD. HYDERABAD INDIA

NOTES:

1 The financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.

2 The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.

3 The above consolidated financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 12 August 2021. The statutory auditors have carried out limited review of the above results for quarter ended 30 June 2021. An unmodified report has been issued by them thereon.

4 Profit before tax includes exceptional items of Rs.281,458 lakhs for the year ended 31 March 2021 consists of:
a. Rs. 309,665 lakhs gain on disposal of business assets of a wholly-owned step-down subsidiary, Natrol LLC, United States of America. Pursuant to the Board's approval on 25 October 2020, the Group entered into a definitive agreement to dispose of business assets of Natrol LLC, as a going concern with related assets, liabilities, products, brands and employees for a cash price of USD 550 million.
b. Rs. 15,285 lakhs gain on account of remeasurement of equity interest in Eugia Pharma Specialties Limited, a joint venture company as at 6 November 2020. The Board in its meeting held on 16 October 2020 decided to enter into a share purchase agreement to acquire 100% equity share capital of MViyes Pharma Ventures Private Limited. MViyes is holding 29.13% shareholding in Eugia Pharma Specialties Limited, a joint venture company in which the Parent Company, through its wholly-owned subsidiary company, is holding 70.87%. By this acquisition, both Eugia Pharma Specialties Limited and MViyes Pharma Ventures Private Limited have become wholly owned subsidiaries.
c. Rs. 43,492 lakhs impairment charges taken considering the difficult economic conditions and the continued impact of Covid 19 in certain markets towards product related intangibles and goodwill.

Tax expenses on the above exceptional item is Rs. 70,489 lakhs. Profit after tax excluding exceptional item (net of tax) for the year ended 31 March 2021 was Rs. 322,414 lakhs.

5 The Group operates in only one segment viz., 'Pharmaceutical Products'.

6 During the quarter, the following companies have been incorporated:
Nurya Brands Inc was incorporated in USA as a wholly owned subsidiary of Auro Health LLC, USA w.e.f 28 April 2021.
Auro Sterlies LLC was incorporated in USA as a wholly owned subsidiary of Aurobindo Pharma USA Inc w.e.f 1 April 2021.
Eugia Injectable Inc was incorporated in USA as a wholly owned subsidiary of Eugia Pharma Specialities Ltd, India w.e.f 1 April 2021.

7 Foreign exchange gain includes exchange difference arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of Ind AS 23 on borrowing costs.

8 The Government of India, on 20 September 2019, vide the Taxation Laws (Amendment) Ordinance 2019, the Ordinance inserted a new Section 115BAA in the Income tax Act, 1961, which provides an option to the Company for paying income tax at reduced rates as per the provisions/conditions defined in the said section. The parent Company is in the process of evaluating the above ordinance and currently the management has proposed to continue with the old tax rates.

9 The Group continues to monitor the possible effects that may result from the pandemic relating to COVID-19. The Group continues to take several business continuity measures with a view to ensure minimal disruption with respect to operations including production and distribution activities. While the Group has experienced certain challenges in certain markets, where the impact of the pandemic is prolonged and business environment is impacted due to the uncertainty, the Group has not experienced any significant difficulties with respect to market demand, financing capital expansion projects, collections or liquidity in other markets. Based on internal and external sources of information, current economic environment and future economic indicators, Group has assessed the financial impact of the COVID-19 situation on its operations particularly on the carrying amounts of receivables, inventories, property, plant and equipment, goodwill and other intangible assets. Wherever considered necessary an assessment of the impact has been carried out and the impact if material on account of impairment have been recorded. However, the impact of the pandemic could be different from those estimated today considering the uncertainties involved. The Group will continue to monitor any material changes to future economic conditions.

10 The date of implementation of the Code of Wages 2019 and Code on Social Security, 2020 is yet to be notified by the Government. The Group is in the process of assessing the impact of these Codes and will give effect in the financial results when the Rules/Schemes thereunder are notified.

11 The figures of the quarter ended 31 March 2021 are the balancing figures between audited figures in respect of the full financial year upto 31 March 2021 and the unaudited published year to date figures upto 31 December 2020 being the date of the end of the third quarter of the financial year. The consolidated results for the nine months ended 31 December 2020 have been subjected to the limited review by the statutory auditors.

12 The Board has approved interim dividend @150% i.e.Re.1.50 (Rupee one and fifty paise only) per equity share of Re.1 (Rupee One only) for the year 2021-22.

By Order of the Board

N. Govindarajan
Managing Director
DIN-00050482

Place: Hyderabad
Date : 12 August 2021

www.aurobindo.com

B S R & Associates LLP
Chartered Accountants

Salarpuriya Knowledge City,
Orwell, B Wing, 6th Floor, Unit-3,
Sy No. 83/1, Plot No. 02, Raidurg,
Hyderabad – 500 081 - India

Telephone: +91 40 7182 2000

Limited Review Report on unaudited quarterly consolidated financial results of Aurobindo Pharma Limited under Regulation 33 of the Listing Regulations

To
Board of Directors of
Aurobindo Pharma Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Aurobindo Pharma Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss of its joint ventures for the quarter ended 30 June 2021 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

S.No.	Name of the component	Country	Relationship
1	APL Healthcare Limited	India	Subsidiary
2	Auronext Pharma Private Limited	India	Subsidiary
3	Auro Peptides Limited	India	Subsidiary
4	APL Pharma Thai Limited	Thailand	Subsidiary
5	All Pharma (Shanghai) Trading Company Limited	China	Subsidiary

S.No.	Name of the component	Country	Relationship
6	Aurobindo Pharma USA Inc.	USA	Subsidiary
7	Aurolife Pharma LLC	USA	Subsidiary
8	Auro Health LLC	USA	Subsidiary
9	Auromedics Pharma LLC	USA	Subsidiary
10	Auro AR LLC	USA	Subsidiary
11	Auro Vaccines LLC	USA	Subsidiary
12	Auro Logistics LLC	USA	Subsidiary
13	Auro Packaging LLC	USA	Subsidiary
14	Aurobindo Pharma Produtos Farmaceuticos Limitada	Brazil	Subsidiary
15	Helix Healthcare B.V.	The Netherlands	Subsidiary
16	Aurogen South Africa (Pty) Ltd	South Africa	Subsidiary
17	Aurobindo Pharma (Pty) Limited	South Africa	Subsidiary
18	Novagen Pharma (Pty) Limited	South Africa	Joint venture
19	Auro Pharma Inc.	Canada	Subsidiary
20	Aurovida Farmaceutica SA DE CV	Mexico	Subsidiary
21	Aurobindo Pharma Japan K.K.	Japan	Subsidiary
22	Aurobindo Pharma Colombia S.A.S	Colombia	Subsidiary
23	Agile Pharma B.V.	The Netherlands	Subsidiary
24	Arrow Generiques SAS	France	Subsidiary
25	1980 Puren Pharma GmbH	Germany	Subsidiary
26	Puren Pharma GmbH & Co., KG	Germany	Subsidiary
27	Aurovitas Spain SA	Spain	Subsidiary
28	Aurobindo Pharma B.V.	The Netherlands	Subsidiary
29	Aurex B.V.	The Netherlands	Subsidiary
30	Aurobindo Pharma GmbH	Germany	Subsidiary
31	Laboratorios Aurobindo S.L.	Spain	Subsidiary
32	Aurobindo Pharma (Italia) S.r. l	Italy	Subsidiary
33	Aurobindo Pharma (Romania) S.r.l.	Romania	Subsidiary
34	Pharmacin B.V.	The Netherlands	Subsidiary
35	Aurobindo Pharma (Malta) Limited	Malta	Subsidiary

S.No.	Name of the component	Country	Relationship
36	APL Swift Services (Malta) Limited	Malta	Subsidiary
37	Milpharm Limited	United Kingdom	Subsidiary
38	Aurovitas Pharma Polska Sp, z.o.o.	Poland	Subsidiary
39	Generis Farmaceutica S.A	Portugal	Subsidiary
40	Generis Phar, Unipessoal Lda.	Portugal	Subsidiary
41	Aurobindo Pharma Saudi Arabia Limited Company	Saudi Arabia	Subsidiary
42	Aurobindo Pharma Industria Farmaceutica Ltda	Brazil	Subsidiary
43	Raidurgam Developers Limited (formerly Aurobindo Antibiotics Ltd)	India	Joint Venture
44	Tergene Biotech Private Limited	India	Joint Venture
45	Auro Pharma India Private Limited	India	Subsidiary
46	Aurovitas Pharma (Taizhou) Ltd	China	Subsidiary
47	Acrotech Biopharma LLC	USA	Subsidiary
48	Purple Bellflower (Pty) Ltd	South Africa	Joint Venture
49	Auroscience (Pty) Ltd	Australia	Subsidiary
50	Auro Science LLC	USA	Subsidiary
51	Apotex Nederland BV.	The Netherlands	Subsidiary
52	Aurovitas spol s.r.o (Formerly known as Apotex (CR) spol.s.r.o)	Czech Republic	Subsidiary
53	Apotex Europe BV	The Netherlands	Subsidiary
54	Sameko Farma B.V.	The Netherlands	Subsidiary
55	Leidapharm B.V.	The Netherlands	Subsidiary
56	Marel B.V.	The Netherlands	Subsidiary
57	Pharma Dossier B.V.	The Netherlands	Subsidiary
58	Aurobindo Pharma FZ LLC	U.A.E.	Subsidiary
59	Curateq Biologics GmbH	Switzerland	Subsidiary
60	Luoxin Aurovitas Pharm (Chengdu) Co., Ltd.	China	Joint Venture
61	Auroactive Pharma Pvt Ltd	India	Subsidiary
62	Aurobindo N.V, Belgium	Belgium	Subsidiary
63	Longxiang Pharma Taizhou Co., Ltd	China	Joint Venture

S.No.	Name of the component	Country	Relationship
64	Novagen BBBEE Invest Co (Pty) Ltd	South Africa	Joint Venture
65	Curateq Biologics Private Limited	India	Subsidiary
66	Auro Cure Private Limited	India	Subsidiary
67	Auro Zest Private Limited	India	Subsidiary
68	Aurobindo Antibiotics Private Limited	India	Subsidiary
69	Eugia Pharma Specialities Limited	India	Subsidiary
70	Mviyes Pharma Ventures Private Limited	India	Subsidiary
71	Lyfius Pharma Private Limited	India	Subsidiary
72	Qule Pharma Private Limited	India	Subsidiary
73	Wytells Pharma Private Limited	India	Subsidiary
74	Auro Steriles LLC (w.e.f 01 April, 2021)	USA	Subsidiary
75	Eugia Injectable Inc , USA (w.e.f 01 April, 2021)	USA	Subsidiary
76	Nurya Brands Inc (w.e.f 28 April 2021)	USA	Subsidiary

5. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. We did not review the interim financial information of 6 subsidiaries included in the Statement, whose interim financial information reflect total revenues (including other income) (before consolidation adjustments) of Rs. 1,35,161 lakhs, total net profit after tax (before consolidation adjustments) of Rs. 10,184 lakhs and total comprehensive income (before consolidation adjustments) of Rs.10,184 lakhs for the quarter ended 30 June 2021 as considered in the consolidated unaudited financial results. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Certain of these subsidiaries are located outside India whose financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's Management has converted the interim financial information of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. Our conclusion in so far on the statement as it relates to the balances and affairs of such subsidiaries located outside India is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

8. The Statement includes the interim financial information of 49 subsidiaries which have not been reviewed, whose interim financial information reflect total revenue (including other income) (before consolidation adjustments) of Rs.149,548 lakhs, total net profit after tax (before consolidation adjustments) of Rs.16,399 lakhs and total comprehensive income (before consolidation adjustments) of Rs.16,399 lakhs for the quarter ended 30 June 2021, respectively, as considered in the Statement. The Statement also includes the Group's share of net loss after tax (before consolidation adjustments) of Rs. 799 lakhs and total comprehensive loss (before consolidation adjustments) of Rs. 799 lakhs for the quarter ended 30 June 2021, respectively, as considered in the consolidated unaudited financial results, in respect of 7 joint ventures , based on their interim financial information which have not been reviewed. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For **B S R & Associates LLP**
Chartered Accountants
Firm Registration Number: 116231W/W-100024

SRIRAM MAHALINGAM
Digitally signed by SRIRAM MAHALINGAM
Date: 2021.08.12 18:25:29 +05'30'

Sriram Mahalingam
Partner
Membership Number: 049642
UDIN:21049642AAAADT5285

Place: Hyderabad
Date: 12 August 2021

AUROBINDO

Annexure - A

S. No	Particulars	Description
1.	List of the entities forming part of the amalgamation / merger, details in brief such as size, turnover etc.	**i) Transferor Companies** a. Auronext Pharma Private Limited ("Auronext") b. Mviyes Pharma Ventures Private Limited ("Mviyes") **ii) Transferee Company** a. Aurobindo Pharma Limited ("APL") iii) The Scheme of Amalgamation provides for amalgamation of the above Transferor Companies with Aurobindo Pharma Limited (Transferee Company). Both the Transferor Companies are wholly owned subsidiaries of the Transferee Company. iv) Turnover/ Revenue for year ended 31 March 2021: a. Auronext – INR 353.57 crores b. Mviyes – Nil c. APL – INR 15,823.68 crores
2.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at 'arm's length'	The Transferor Companies are wholly owned subsidiaries of the Transferee Company. The proposed Scheme of Amalgamation being dealt under the specific sections of the Companies Act, 2013, does not fall within the purview of related party transaction pursuant to the circular No.30/2014 dated 17 July 2014 issued by the Ministry of Corporate Affairs. Further, being the Scheme of Amalgamation between holding company and its wholly owned subsidiary companies, pursuant to the provisions of Regulations 23(5)(b) of SEBI LODR Regulations, 2015, it is exempt from the relevant provisions of related party transactions under the said SEBI LODR Regulations, 2015 as well as from the provisions of SEBI circular dated 10 March 2017.
3.	Area of business of the entities	The Transferor Companies and Transferee Company are engaged in the business of manufacturing of pharmaceutical products,
4.	Rationale for amalgamation / merger	The Transferee Company is holding 100% stake directly in the Transferor Companies, as the Transferor Companies and Transferee Company's business activities are similar and complement each other, and to achieve *inter-alia* economies of scale and efficiency, the merger of the companies is being undertaken. The amalgamation of the Transferor Companies

		with the Transferee Company would *inter-alia* have the following benefits: (i) The amalgamation will enable appropriate consolidation of activities of Transferor Companies and Transferee Company with pooling and more efficient utilization of their resources, greater economies of scale, reduction in overheads and other expenses and improvement in various operating parameters. (ii) To achieve consolidation, greater integration and flexibility which will maximize overall shareholder value and improve the competitive position of the combined entity. (iii) To achieve greater efficiency in cash management and unfettered access to cash flows generated by the combined entity which can be deployed more effectively to fund organic and inorganic growth opportunities. (iv) Improved organizational capability and leadership, arising from the pooling of human capital who have the diverse skills, talent and vast experience to compete successfully in an increasingly competitive industry. (v) Greater access by the Transferee Company to different market segments in conduct of its business. (vi) Cost savings are expected to flow from more focused operational efforts, rationalization, standardization and simplification of business processed, elimination of duplication and rationalization of administrative expenses. (vii) The amalgamation will result in reduction of multiplicity of entities, thereby reducing compliance cost of multiple entities viz., statutory filings, regulatory compliances, labour law/ establishment related compliances.
5.	In case of cash consideration - amount or otherwise share exchange ratio	Since the Transferor Companies are wholly owned subsidiaries of the Transferee Company, no shares of the Transferee Company shall be allotted under the Scheme of Amalgamation.
6.	Brief details of change in shareholding pattern (if any) of listed entity	There would be no change in shareholding pattern of the Transferee Company.

AUROBINDO

Annexure -B

a) Name of the target entity, details in brief such as size, turnover etc.;	**i) Name of the Target:** Cronus Pharma Specialities India Private Limited. **Registered Office:** Plot No. 1-98/5/78, Jubilee Enclave Madhapur, Hitech City, Hyderabad, Telangana 500081 Cronus Pharma LLC (100% subsidiary of Cronus Pharma Specialities India Private Limited, based in US) **ii) Details of the Target:** Cronus Pharma Specialities India Private Limited ("Cronus") was incorporated on September 2, 2015. It has built a dedicated non-sterile and sterile manufacturing facility focused on veterinary pharmaceutical products for regulated markets in SEZ, spanning an area of 10 Acres with dedicated manufacturing blocks for various dosage forms. The plant awaits regulatory inspections and will commence commercial production upon regulatory approval. Cronus has 67 products in its pipeline, of which 22 have been filed and 6 have been approved by the Centre for Veterinary Medicine, USFDA. Cronus also generates income as a CRO (Custom Research Organisation). • Turnover for the financial year: 2019-20 - Rs.6.6 Crores 2020-21 - Rs.11.4 Crores
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length";	Acquisition will not fall within the related party transaction.
c) Industry to which the entity being acquired belongs;	Cronus is engaged in the development, manufacturing and sale of generic veterinary pharmaceutical products and CRO services.
d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The Target company is in the business of veterinary pharmaceutical formulation business catering to export markets and complements the Company's product offerings in the regulated markets. The acquisition will provide the Company a foothold in the US$48 Billion global animal health market. Cronus has 67 products in its pipeline, of which 22 have been filed and 6 have been approved by the Centre for Veterinary Medicine, USFDA.

e) Brief details of any governmental or regulatory approvals required for the acquisition;	Prior approval of the Unit Approval Committee (UAC) under SEZ section, Department of Commerce, Ministry of Commerce and Industry, Government of India, subject to the terms and conditions specified in SEZ Instructions 2018.
f) Indicative time period for completion of the acquisition;	Within 8 weeks, subject to completion of closing conditions.
g) Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
h) Cost of acquisition or the price at which the shares are acquired;	Rs.420 Crores (subscription of 95,059,963 equity shares of Rs.10/- each at a premium of Rs.34.18 per equity share)
i) Percentage of shareholding / control acquired and / or number of shares acquired;	After subscription, the Company will own 51% of the equity share capital of Cronus Pharma Specialities India Private Limited.
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	• Cronus is a pharmaceutical company developing, manufacturing and distributing generic veterinary pharmaceutical products. Cronus has a factory at Hyderabad. Cronus has 67 products in its pipeline, of which 22 have been filed and 6 have been approved by the Centre for Veterinary Medicine, USFDA. • Cronus was incorporated in September 2015 and the target company, and its subsidiary have presence in India and USA • The manufacturing facility awaits USFDA audit and subsequent clearance. • Turnover for the financial years: 2019-20 - Rs.6.6 crores 2020-21 - Rs.11.4 crores In connection with the acquisition of Cronus Pharma Specialities India Private Limited by the Company, PricewaterhouseCoopers Business Consulting Services LLP has been engaged by the Company to advise it in connection with valuation of Cronus Pharma, and Pricewaterhouse Coopers Services LLP has been engaged by the Company to advise it in connection with carrying out financial and tax due diligence on Cronus Pharma. PricewaterhouseCoopers Business Consulting Services LLP and Pricewaterhouse Coopers Services LLP are member firms of the network of PricewaterhouseCoopers firms and entities, each of which is a separate and independent legal entity. DSK Legal acted as the legal counsel on this transaction.

PRESS RELEASE

12th August 2021, Hyderabad, India

Aurobindo Pharma Ltd: Q1 FY22 Consolidated Financial Results (ex-Natrol)

(Amount in INR Cr)	Q1 FY22	Q1 FY21	% Chg (YoY)	Q4 FY21	% Chg (QoQ)
Revenue from operations	5,702.0	5,539.9	2.9%	6,007.1	-5.1%
EBITDA before Forex and Other income	1,209.4	1,145.4	5.6%	1,276.4	-5.2%
EBITDA margin (%)	21.2%	20.7%		21.2%	
PBT before JV, Forex and Exceptional items	998.1	976.9	2.2%	1,055.8	-5.5%
Net Profit	770.0	707.3	8.9%	802.1	-4.0%

Note: Consolidated financials exclude Natrol for ease of comparison

Key highlights of Q1 FY22 (ex-Natrol)

- Revenue from Operations at INR 5,702 Cr increased by 2.9% over corresponding period last year. During FY21, the Natrol business was divested.
  - US formulations revenue remained largely flat on a YoY basis at INR 2,681.2 Cr
  - Europe formulation revenue stood at INR 1,582.9 Cr, an increase of 19.7% over corresponding previous quarter
  - Growth Markets registered a growth of 13.7% YoY to INR 329.3 Cr
  - ARV revenue declined by 30.3% YoY to INR 296.4 Cr
  - API revenue for the quarter was at INR 812 Cr vs. INR 780.1 Cr in the corresponding previous period
- EBIDTA before Forex and Other income stood at INR 1,209.4 Cr, an increase of 5.6 YoY; EBITDA margin for the quarter was 21.2%
- Research & Development (R&D) spend at INR 358 Cr, 6.3% of revenues
- Received final approval for 4 ANDAs from USFDA including 3 injectables
- Net Profit stood at INR 770 Cr as against INR 707.3 Cr in the corresponding previous period
- Basic & Diluted EPS is INR 13.14 per share
- The Board declared an interim dividend of INR 1.50 per share


Commenting on the Company's performance, Mr. N. Govindarajan, Managing Director of the company said: *"The quarter's performance reflected the resilience in our operations amidst the current challenging times. We remain focused on ensuring business continuity on the operations front and to resolve regulatory issues in some of our facilities. Our business is well prepared to navigate the journey towards profitable growth and we look forward to execute on our key growth pillars."*


Operational Performance (Consolidated)

(Amount in INR Cr)	Q1 FY22	Q1 FY21	% Chg (YoY)	Q4 FY21	% Chg (QoQ)
Formulations					
USA	2,681.2	2,722.2	-1.5%	2,861.5	-6.3%
Europe	1,582.9	1,322.2	19.7%	1,552.6	2.0%
Growth Markets	329.3	289.6	13.7%	305.7	7.7%
ARV	296.4	425.5	-30.3%	491.2	-39.7%
Total Formulations	**4,889.8**	**4,759.5**	**2.7%**	**5,211.0**	**-6.2%**
Active Pharmaceutical Ingredients (API)					
Betalactum	383.6	500.3	-23.3%	408.6	-6.1%
Non Betalactum	428.3	279.8	53.1%	385.7	11.1%
Total API	**811.9**	**780.1**	**4.1%**	**794.3**	**2.2%**
Consolidated Gross Sales	**5,701.7**	**5,539.6**	**2.9%**	**6,005.3**	**-5.0%**
Dossier Income	0.2	0.3	-33.3%	1.8	-88.9%
Revenue from operations	**5,702.0**	**5,539.9**	**2.9%**	**6,007.1**	**-5.1%**

Note: Operational Performance exclude Natrol for ease of comparison

Q1 FY22: Consolidated revenue breakup - Geography & Segment wise





Formulations

Formulation revenue for continuing operations for the quarter increased by 2.7% YoY to INR 4,889.8 Cr and accounted for 85.8% of total revenues.

US Formulations

- In Q1 FY22, US revenue declined by 1.5% YoY to INR 2,681.2 Cr and accounted for 47% of consolidated revenues
- Filed 8 ANDAs including 2 injectables with USFDA in Q1 FY22
- Received final approval for 4 ANDAs including 3 injectables in Q1 FY22
- As on 30th June 2021, on a cumulative basis, the company filed 654 ANDAs with USFDA and received approval for 480 ANDAs including 29 tentative* approvals
- The company has launched 5 products during the quarter including 2 injectables

**Tentative approvals include 8 ANDAs approved under PEPFAR.*

Europe Formulations

- Europe revenue in Q1 FY22 posted a growth of 19.7% YoY to INR 1,582.9 Cr. Europe Formulations accounted for 27.8% of consolidated revenues.

ARV Formulations

- ARV business revenue for Q1 FY22 was at INR 296.4 Cr compared to INR 425.5 Cr in Q1 FY21, a decrease of 30.3% YoY and accounted for 5.1% of total revenues. The business was affected by higher stocking on advanced procurement last year, amid Covid-19 uncertainties by multilateral agencies.

Growth Markets Formulations

- Revenue from Growth Markets formulations in Q1 FY22 grew by 13.7% YoY to INR 329.3 Cr and accounted for 5.8% of revenue. The quarter's performance was led by strong growth in Brazil and South African business.

Active Pharmaceutical Ingredients (API)

- In Q1 FY22, API business posted a revenue of INR 812 Cr, an increase of 4.1% YoY and contributed 14.2% to the consolidated revenues
- The company filed 1 DMFs with USFDA during the quarter.

Global Regulatory Filings

Filings	Q1 FY22	Cumulative Filings as on 30th Jun 2021
ANDAs (including filings from Aurobindo USA)	8	654
DMFs (including filings from AuroNext and Auro Peptides)	1	252
Formulations Dossiers in other key advanced markets (incl. multiple registrations in Europe, South Africa and Canada)	102	4,009
API DMF/COS filings in other key regulated markets (incl. multiple registrations)	45	3,309

USFDA Approvals Received in Q1 FY22

Final Approvals

#	Product	Therapy
1	Dorzolamide HCL & Timolol Maleate Ophthalmic Sol (gCosopt) 2%/0.5% w/v	Anti-Glaucoma
2	Nicardipine HCL Inj (gCardene) 25mg / 10ml	CVS
3	Ephedrine Sulphate Inj (gAkovaz) 50mg / ml	CVS
4	Docetaxel Inj 20mg / 2ml (SDV) and 80mg / 8ml & 160mg / 16ml	Oncology

Q1 FY22 Earnings Call Details

The company will host an earnings call at **8.30 AM IST on 13th August 2021**, to discuss the performance and answer any questions from participants.

Participants can dial-in on the numbers below:
Primary Numbers: +91 22 6280 1437 / +91 22 7115 8825

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) headquartered at Hyderabad, India, develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, EU, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up. The Company is marketing these products globally in over 150 countries.

For further information, please contact:
Arvind Bothra
Head - Investor Relations | Corporate Communications
Phone: 040-66725401 / 66725000
Email: ir@aurobindo.com

AUROBINDO

AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)
Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India
Tel: +91 040 23736370; Fax: +91 40 23747340; Email: info@aurobindo.com (Rs. In lakhs)

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2021

	Particulars	Quarter ended			Year ended
		30.06.2021	31.03.2021	30.06.2020	31.03.2021
		Unaudited	Audited	Unaudited	Audited
1	**Revenue from operations**				
	(a) Net sales/ income from operations	**5,69,185**	5,99,168	5,83,523	24,55,795
	(b) Other operating income	**1,013**	982	8,955	21,668
	Total revenue from operations	**5,70,198**	6,00,150	5,92,478	24,77,463
2	**Other income**				
	(a) Foreign exchange gain (net) (refer note 7)	**2,859**	1,423	2,222	10,358
	(b) Others	**8,131**	6,387	9,337	27,726
	Total other income	**10,990**	7,810	11,559	38,084
	Total income (1+2)	**5,81,188**	6,07,960	6,04,037	25,15,547
3	**Expenses**				
	(a) Cost of materials consumed	**1,86,005**	1,99,014	2,09,817	8,31,727
	(b) Purchase of stock-in-trade	**37,324**	49,225	60,157	2,31,542
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	**13,294**	(7,530)	(29,234)	(73,021)
	(d) Employee benefits expense	**86,993**	85,440	88,799	3,53,502
	(e) Finance costs	**1,288**	1,822	2,107	7,449
	(f) Foreign exchange loss (net) (refer note 7)	**-**	-	-	-
	(g) Depreciation and amortisation expense	**27,969**	26,600	25,552	1,05,538
	(h) Other expenses	**1,25,644**	1,46,534	1,37,204	6,00,372
	Total expenses	**4,78,517**	5,01,105	4,94,402	20,57,109
4	**Profit before share of profit of joint ventures, exceptional items and tax (1+2-3)**	**1,02,671**	1,06,855	1,09,635	4,58,438
5	Share of loss of joint ventures, net of tax	**(900)**	(837)	(1,200)	(5,536)
6	**Profit before exceptional items and tax (4+5)**	**1,01,771**	1,06,018	1,08,435	4,52,902
7	**Exceptional items (refer note 4)**	**-**	(69)	-	(2,81,458)
8	**Profit before tax (6-7)**	**1,01,771**	1,06,087	1,08,435	7,34,360
9	**Tax expense**				
	Current tax	**24,316**	44,923	36,525	2,32,536
	Tax credit - Minimum Alternate Tax (MAT)	**(2,063)**	(354)	-	(354)
	Deferred tax	**2,521**	(18,600)	(6,406)	(31,205)
	Total tax expense	**24,774**	25,969	30,119	2,00,977
10	**Profit for the period/year (8-9)**	**76,997**	80,118	78,316	5,33,383
11	Other Comprehensive Income				
	A) Items that will not be reclassified subsequently to profit or loss:				
	i) Re-measurement of defined employee benefit liability	**(246)**	(232)	(482)	(980)
	ii) Income-tax relating to items that will not be reclassified to profit or loss	**86**	102	169	370
	(iii) Equity investments through other comprehensive income – net change in fair value	**1,291**	(339)	-	(359)
	B) Items that will be reclassified subsequently to profit or loss:				
	i) Exchange differences on translating the financial statements of foreign operations	**22,002**	(8,137)	6,426	1,443
	ii) Income-tax on items that will be reclassified subsequently to profit or loss	**-**	-	-	-
	Total other comprehensive income for the period/year (net of tax)	**23,133**	(8,606)	6,113	474
12	**Total Comprehensive income for the period/year (net of tax) (10+11)**	**1,00,130**	71,512	84,429	5,33,857
	Attributable to:				
	Owners of the Parent Company	**1,00,130**	71,552	84,419	5,33,959
	Non-controlling interest	**-**	(40)	10	(102)
	Out of total comprehensive income above,				
	Profit for the year attributable to:				
	Owners of the Parent Company	**76,997**	80,158	78,306	5,33,485
	Non-controlling interest	**-**	(40)	10	(102)
	Other comprehensive income attributable to:				
	Owners of the Parent Company	**23,133**	(8,606)	6,113	474
	Non-controlling interest	**-**	-	-	-
13	Paid-up equity share capital (face value Re. 1 per share)	**5,859**	5,859	5,859	5,859
14	Other equity				21,87,127
15	Earnings per equity share (face value Re. 1 per share)	**(not annualised)**	(not annualised)	(not annualised)	(Annualised)
	(a) Basic (in Rs.)	**13.14**	13.67	13.32	91.04
	(b) Diluted (in Rs.)	**13.14**	13.67	13.32	91.04

NOTES:

1 The financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.

2 The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.

3 The above consolidated financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 12 August 2021. The statutory auditors have carried out limited review of the above results for quarter ended 30 June 2021. An unmodified report has been issued by them thereon.

4 Profit before tax includes exceptional items of Rs.281,458 lakhs for the year ended 31 March 2021 consists of:
a. Rs. 309,665 lakhs gain on disposal of business assets of a wholly-owned step-down subsidiary, Natrol LLC, United States of America. Pursuant to the Board's approval on 25 October 2020, the Group entered into a definitive agreement to dispose of business assets of Natrol LLC, as a going concern with related assets, liabilities, products, brands and employees for a cash price of USD 550 million.
b. Rs. 15,285 lakhs gain on account of remeasurement of equity interest in Eugia Pharma Specialties Limited, a joint venture company as at 6 November 2020. The Board in its meeting held on 16 October 2020 decided to enter into a share purchase agreement to acquire 100% equity share capital of MViyes Pharma Ventures Private Limited. MViyes is holding 29.13% shareholding in Eugia Pharma Specialties Limited, a joint venture company in which the Parent Company, through its wholly-owned subsidiary company, is holding 70.87%. By this acquisition, both Eugia Pharma Specialties Limited and MViyes Pharma Ventures Private Limited have become wholly owned subsidiaries.
c. Rs. 43,492 lakhs impairment charges taken considering the difficult economic conditions and the continued impact of Covid 19 in certain markets towards product related intangibles and goodwill.

Tax expenses on the above exceptional item is Rs. 70,489 lakhs. Profit after tax excluding exceptional item (net of tax) for the year ended 31 March 2021 was Rs. 322,414 lakhs.

5 The Group operates in only one segment viz., 'Pharmaceutical Products'.

6 During the quarter, the following companies have been incorporated:
Nurya Brands Inc was incorporated in USA as a wholly owned subsidiary of Auro Health LLC, USA w.e.f 28 April 2021.
Auro Steriles LLC was incorporated in USA as a wholly owned subsidiary of Aurobindo Pharma USA Inc w.e.f 1 April 2021.
Eugia Injectable Inc was incorporated in USA as a wholly owned subsidiary of Eugia Pharma Specialities Ltd, India w.e.f 1 April 2021.

7 Foreign exchange gain includes exchange difference arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of Ind AS 23 on borrowing costs.

8 The Government of India, on 20 September 2019, vide the Taxation Laws (Amendment) Ordinance 2019, the Ordinance inserted a new Section 115BAA in the Income tax Act, 1961, which provides an option to the Company for paying income tax at reduced rates as per the provisions/conditions defined in the said section. The parent Company is in the process of evaluating the above ordinance and currently the management has proposed to continue with the old tax rates.

9 The Group continues to monitor the possible effects that may result from the pandemic relating to COVID-19. The Group continues to take several business continuity measures with a view to ensure minimal disruption with respect to operations including production and distribution activities. While the Group has experienced certain challenges in certain markets, where the impact of the pandemic is prolonged and business environment is impacted due to the uncertainty, the Group has not experienced any significant difficulties with respect to market demand, financing capital expansion projects, collections or liquidity in other markets. Based on internal and external sources of information, current economic environment and future economic indicators, Group has assessed the financial impact of the COVID-19 situation on its operations particularly on the carrying amounts of receivables, inventories, property, plant and equipment, goodwill and other intangible assets. Wherever considered necessary an assessment of the impact has been carried out and the impact if material on account of impairment have been recorded. However, the impact of the pandemic could be different from those estimated today considering the uncertainties involved. The Group will continue to monitor any material changes to future economic conditions.

10 The date of implementation of the Code of Wages 2019 and Code on Social Security, 2020 is yet to be notified by the Government. The Group is in the process of assessing the impact of these Codes and will give effect in the financial results when the Rules/Schemes thereunder are notified.

11 The figures of the quarter ended 31 March 2021 are the balancing figures between audited figures in respect of the full financial year upto 31 March 2021 and the unaudited published year to date figures upto 31 December 2020 being the date of the end of the third quarter of the financial year. The consolidated results for the nine months ended 31 December 2020 have been subjected to the limited review by the statutory auditors.

12 The Board has approved interim dividend @150% i.e.Re.1.50 (Rupee one and fifty paise only) per equity share of Re.1 (Rupee One only) for the year 2021-22.

By Order of the Board

N. Govindarajan
Managing Director
DIN-00050482

Place: Hyderabad
Date : 12 August 2021

www.aurobindo.com